Pair page
Argireline with Decapeptide-12
Mechanism-tag overlap and published literature for Argireline and Decapeptide-12, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Argireline unique
snap-25-mimetic
Shared
cosmetic-peptide
Decapeptide-12 unique
tyrosinase-inhibitor
Quick facts
Argireline
RouteTopical only (cosmetic)
Half-lifeNot listed
FDA statusCosmetic ingredient (not a drug)
WADAN/A (topical cosmetic)
Decapeptide-12
RouteTopical only
Half-lifeNot listed
FDA statusCosmetic ingredient
WADAN/A (topical cosmetic)
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Argireline | Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025 Jun 14;26(12):5722. doi: 10.3390/ijms26125722. PMID: 40565185. (Most recent systematic review; formulation science is the domin… PMID 40565185 | systematic review |
| 2019 | Argireline | Choi SY, Kwon HJ, Ahn GR, Ko EJ, Yoo KH, Kim BJ, Lee C, Kim D. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Ann Dermatol. 2019 Jun;31(3):263-271. doi: 10.5021/ad.2019.31.3.263.… PMID 33911590 | human trial |
| 2017 | Argireline | Raikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Cosmet Dermatol. 2017 Jun;16(2):271-278. doi: 10.1111/jocd.12314. PMID: 28150423. (Four-ar… PMID 28150423 | human trial |
| 2013 | Argireline | Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013 Apr;14(2):147-153. doi: 10.1007/s40257-013-0009-9. PMID: 23417317. (The largest ran… PMID 23417317 | human trial |
| 2013 | Argireline | Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013 Mar;20(3):515-518. doi: 10.1111/ene.12009. PMID: 23146065. (NIH / NIN… PMID 23146065 | human trial |
| 2002 | Argireline | Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-310. doi: 10.1046/j.1467-2494.2002.00153.x. PMID: 184985… PMID 18498523 | human pilot |
| 2013 | Argireline | Wang Y, Wang M, Xiao XS, Pan P, Li P, Huo J. The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects. J Cosmet Laser Ther. 2013 Aug;15(4):237-241. doi: 10.3109/14764172.2013.769273. PMID: 23607739. (Companion murine / clinical paper — D-galactose-aged… PMID 23607739 | preclinical, in vivo |
| 2015 | Argireline | Kraeling MEK, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015 Mar;34(1):46-52. doi: 10.3109/15569527.2014.894521. PMID: 24754410. (Independent FDA in vitro penetration study — ~0.22% of 10% appl… PMID 24754410 | preclinical, in vitro |
| 2021 | Argireline | Lim SH, Kathuria H, Amir MHB, Zhang X, Duong HTT, Ho PCL, Kang L. High resolution photopolymer for 3D printing of personalised microneedle for transdermal delivery of anti-wrinkle small peptide. J Control Release. 2021 Jan 10;329:907-918. doi: 10.1016/j.jconrel.2020.10.021. PMID… PMID 33068646 | pharmacology |
| 2020 | Argireline | Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020 Oct 26;8:572923. doi: 10.3389/fchem.2020.572923. PMID: 33195060. (Contextual review of cosmetic-peptide biochemistry and categorisation;… PMID 33195060 | review |
| 2024 | Argireline | Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis. JMIR Dermatol. 2024;7:e54217. doi: 10.2196/54217. PMID: 38376906. (Google Trends analysis 2013-2023; post-2022 TikTok-driven consumer search surge; coining of "Botox in a bottle" in popular culture.) PMID 38376906 | research article |
| 2020 | Argireline | Lim SH, Tiew WJ, Zhang J, Ho PC, Kachouie NN, Kang L. Geometrical optimisation of a personalised microneedle eye patch for transdermal delivery of anti-wrinkle small peptide. Biofabrication. 2020;12(3):035003. doi: 10.1088/1758-5090/ab6d37. PMID: 31952064. (3D-printed personalis… PMID 31952064 | research article |
| 2018 | Decapeptide-12 | Jiang L, Hino PD, Bhatia A, Stephens TJ, Jimenez F. Efficacy of Trifecting Night Cream, a novel triple-acting skin brightening product: a double-blind, placebo-controlled clinical study. J Clin Aesthet Dermatol. 2018;11(12):25-30. (Envy Medical triple-action cream containing dec… | human trial |
| 2009 | Decapeptide-12 | Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. 2009;8(8):732-735. PMID: 19663110. (Pivotal split-face RCT pilot in five Fitzpatrick IV fema… PMID 19663110 | human trial |
| 2013 | Decapeptide-12 | Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, Echeverry HF. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. J Drugs Dermato… PMID 23839199 | human pilot |
| 2012 | Decapeptide-12 | Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. PMID: 22527440. (Open-label evaluation of the full Lumixyl brightening system in mild-to-moderate facial melasma.) PMID 22527440 | human pilot |
| 2012 | Decapeptide-12 | Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12 (24-week photodamage study). J Drugs Dermatol. 2012. PMID: 22401652. (24-week open-label in photodamaged facial hyperpigmentation; subset-shift improvements in grade-4 severe… PMID 22401652 | human pilot |
| 2012 | Decapeptide-12 | Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg. 2012;38(7 Pt 1):971-984. PMID: 22583339. (Hantash-co-authored contemporary melasma-therapeutics review that situates decapeptide-12 within the broader depigmentin… PMID 22583339 | human study |
| 2019 | Decapeptide-12 | Hantash BM, Abu Ubeid A. Tyrosinase inhibitors with potent anti-senescence activity in human neonatal keratinocyte progenitors. 2019. (Extends decapeptide-12 mechanistic claims into SIRT-pathway anti-senescence in human keratinocytes — supports "brightening plus anti-aging" posi… | preclinical, in vitro |
| 2009 | Decapeptide-12 | Abu Ubeid A, Zhao L, Wang Y, Hantash BM. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol. 2009;129(9):2242-2249. PMID: 19440221. (Foundational discovery paper — phage-display biopanning that identified decapeptide-12… PMID 19440221 | preclinical, in vitro |
| 1993 | Decapeptide-12 | Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB. Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol. 1993;100(6):806-811. (Classic determinant-of-pigmentation paper establishing tyrosinase as the rate-limiting enzyme o… | preclinical, in vitro |
| 2016 | Decapeptide-12 | Ochiai A, Tanaka S, Tanaka T, Taniguchi M. New tyrosinase inhibitory decapeptide: molecular insights into the role of tyrosine residues. J Biosci Bioeng. 2016;121(6):607-613. (Independent decapeptide-class tyrosinase-inhibitor work highlighting the role of tyrosine residues in t… | mechanism / discovery |
| 2012 | Decapeptide-12 | Ubeid AA, Do S, Nye C, Hantash BM. Potent low toxicity inhibition of human melanogenesis by novel indole-containing octapeptides. Biochim Biophys Acta. 2012;1820(10):1481-1489. (Extended structure-activity work from the Hantash group on the peptide-tyrosinase inhibitor scaffold.) | mechanism / discovery |
| 2014 | Decapeptide-12 | Ubeid AA, Hantash BM. Minireview: Peptide analogs and short sequence oligopeptides as modulators of skin pigmentation. Curr Top Med Chem. 2014;14(12):1418-1424. PMID: 24894693. (Review of tyrosinase-inhibitor oligopeptides and α-MSH analogs in cosmetic and dermatologic pigment m… PMID 24894693 | review |
Related pair pages
More research context
Frequently asked
Have Argireline and Decapeptide-12 been studied together?
No co-administration studies between Argireline and Decapeptide-12 are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Argireline and Decapeptide-12 share?
Argireline and Decapeptide-12 share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Argireline and Decapeptide-12?
Argireline: Cosmetic ingredient (not a drug). Decapeptide-12: Cosmetic ingredient. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Argireline and Decapeptide-12?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Argireline profile and the Decapeptide-12 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026